What is HC Wainwright’s Estimate for DMAC Q1 Earnings?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Equities research analysts at HC Wainwright issued their Q1 2026 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Monday, November 17th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings per share of ($0.18) for the quarter. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2029 earnings at $0.15 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02).

Several other research firms also recently commented on DMAC. Cowen assumed coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating on the stock. TD Cowen began coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They set a “buy” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Cantor Fitzgerald assumed coverage on DiaMedica Therapeutics in a report on Friday. They issued an “overweight” rating for the company. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

DiaMedica Therapeutics Price Performance

DMAC stock opened at $6.90 on Tuesday. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $7.49. The stock has a market capitalization of $359.33 million, a price-to-earnings ratio of -10.00 and a beta of 1.42. The business’s fifty day moving average price is $6.75 and its two-hundred day moving average price is $5.30.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Strs Ohio grew its position in shares of DiaMedica Therapeutics by 19.7% in the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after buying an additional 1,500 shares during the last quarter. World Investment Advisors increased its position in DiaMedica Therapeutics by 7.3% during the 3rd quarter. World Investment Advisors now owns 34,325 shares of the company’s stock valued at $236,000 after purchasing an additional 2,350 shares during the period. Rhumbline Advisers lifted its position in shares of DiaMedica Therapeutics by 14.5% in the 3rd quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock worth $188,000 after purchasing an additional 3,463 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of DiaMedica Therapeutics by 24.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock valued at $74,000 after purchasing an additional 3,709 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of DiaMedica Therapeutics by 44.2% during the third quarter. Bank of America Corp DE now owns 12,249 shares of the company’s stock worth $84,000 after buying an additional 3,752 shares during the period. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg purchased 338,265 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were purchased at an average cost of $6.00 per share, with a total value of $2,029,590.00. Following the completion of the purchase, the insider owned 7,654,045 shares of the company’s stock, valued at $45,924,270. This trade represents a 4.62% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders bought 556,645 shares of company stock valued at $3,335,552. 7.30% of the stock is owned by corporate insiders.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.